Tesamorelin
Also known as Egrifta
A GHRH analog FDA-approved (as Egrifta) to reduce visceral abdominal fat in HIV lipodystrophy, used off-label for body composition.
Evidence grade A · 9 citations · Last reviewed October 2026
- Regulatory status
- FDA-approved for HIV-associated lipodystrophy as EGRIFTA SV (1.4 mg daily) and EGRIFTA WR (1.28 mg daily) — two current products with different labeled doses. Any other use is off-label.
- Common routes
- Subcutaneous injection
Tesamorelin: the quick answer
- What is Tesamorelin?
- A synthetic analog of growth hormone-releasing hormone (GHRH) that raises the body's own growth hormone. Brand name Egrifta.
- How strong is the evidence?
- Strong for one use: phase 3 randomized trials showed it reduces visceral (deep belly) fat in adults with HIV-associated lipodystrophy. Other uses rest on smaller or secondary data.
- US status (as of October 2026)
- FDA-approved, as EGRIFTA SV and EGRIFTA WR, to reduce excess abdominal fat in adults with HIV and lipodystrophy. Every other use, including weight loss in people without HIV, is off-label.
Overview
Tesamorelin (brand name Egrifta) is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH) that is FDA-approved for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is the only GHRH analog with a full FDA approval backed by phase 3 clinical trial data. The drug consists of the full 44-amino-acid sequence of human GHRH(1-44) fused to a trans-2-hexenoic acid moiety at the N-terminus that confers stability against enzymatic degradation, extending its plasma half-life to approximately 26-38 minutes — meaningfully longer than native GHRH.
HIV-associated lipodystrophy is characterized by pathological accumulation of visceral adipose tissue (VAT), often alongside peripheral fat loss (lipoatrophy), and is driven in part by antiretroviral therapy and HIV-associated relative GH deficiency. Tesamorelin restores physiological pulsatile GH secretion and the downstream rise in IGF-1, which promotes lipolysis preferentially in visceral depots. The pivotal phase 3 trials demonstrated significant and durable reductions in VAT on computed tomography (CT) compared to placebo, leading to FDA approval in 2010.
Off-label, tesamorelin is explored for visceral fat reduction in non-HIV populations (obesity, GH deficiency), improvement of liver fat (NAFLD/MASLD), and potential metabolic and cognitive benefits via GH/IGF-1 normalization. Compounded tesamorelin is available through telehealth providers in the United States but carries less standardization than the branded Egrifta formulation. Evidence grade: **A** for HIV-associated lipodystrophy (FDA-approved, multiple phase 3 RCTs); **B** for off-label metabolic indications (mechanistically supported, smaller or non-primary-endpoint data).
Where to get Tesamorelin
Every telehealth provider we track that offers Tesamorelin. Partners we work with are shown first.
Live Vital
Best for: low-cost, physician-led compounded GLP-1 with peptide and hormone options
Editorial score · methodology
Direct Meds
Best for: listed for disclosure only; see its FDA warning and BBB complaints first
Editorial score · methodology
Pepti
Best for: a low all-in starter price on compounded GLP-1s, with every dose price published up front
Editorial score · methodology
Trellis Vitality
Best for: body-composition tracking and flat per-dose pricing without a membership fee
Editorial score · methodology
Longevixx
Best for: one flat price at every dose across four GLP-1 formats, with a dietitian visit included
Editorial score · methodology
SUROS Rx
Best for: published monthly and quarterly compounded GLP-1 prices with a named medical group and pharmacy
Editorial score · methodology
Dr. Gillis' Wellness Center
Best for: Central Maine patients wanting a walk-in, doctor-led GLP-1 clinic with free follow-ups
Editorial score · methodology
Editorial score · methodology
RxPepsDirect
Best for: Lowest per-vial GLP-1 cost: sema $25, tirz $45, $39 telehealth Rx, 28 states
Editorial score · methodology
Vyora Wellness
Best for: people who want coaching included and a flat price that doesn't rise with dose
Editorial score · methodology
Vitakey
Best for: low-cost compounded semaglutide or tirzepatide if you are fine prepaying for 3 months
Editorial score · methodology
Editorial score · methodology
Also offered by 3 more providers we track
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
What does Tesamorelin do? Claims vs evidence
Each row is a claim as it is commonly marketed, the strongest kind of evidence behind it, and what that evidence found. Numbers in brackets point to the sources at the end of this page.
| Claim | Evidence | What the studies found | Sources |
|---|---|---|---|
| Reduces belly (visceral) fat | FDA-approved use | In a 412-patient randomized trial in people with HIV, visceral fat fell 15.2% over 26 weeks on tesamorelin 2 mg a day and rose 5.0% on placebo. The approval covers HIV-associated lipodystrophy only. | Sources:[1] |
| Keeps belly fat off | Human studies | In a 404-patient trial, visceral fat was about 18% lower after 12 months of continued use, and the gains of the first six months were rapidly lost in people switched to placebo. | Sources:[2] |
| Reduces liver fat | Human studies | A 2026 meta-analysis of five randomized trials in adults with HIV found liver fat fell by 4.28 percentage points versus placebo. Liver fat is not an approved use. | Sources:[5] |
| Builds lean muscle | Human studies | The same meta-analysis found lean body mass rose 1.42 kg versus placebo in adults with HIV, with no significant change in BMI or subcutaneous fat. | Sources:[5] |
| Sharpens memory and thinking | Human studies | In a 20-week trial of 152 adults aged 55 to 87, tesamorelin 1 mg a day improved a combined cognition score versus placebo, mainly executive function. One trial; not an approved use. | Sources:[7] |
Evidence levels, strongest first: FDA-approved use, human studies (of any size or design), animal studies, cell studies only, and no direct evidence (nothing tests the claim for this compound).
How it works
Tesamorelin binds GHRH receptors (GHRHR) on anterior pituitary somatotrophs, activating adenylyl cyclase and cAMP-dependent signaling that drives pulsatile GH secretion. Unlike synthetic GH (somatropin), tesamorelin does not bypass the hypothalamic-pituitary axis — it amplifies the body's own GH pulses, preserving feedback regulation via somatostatin and endogenous IGF-1. This means GH levels rise within physiological range rather than to the supraphysiological levels seen with exogenous GH injection, which may explain the relatively favorable safety profile in clinical trials [1].
Elevated GH directly stimulates hepatic production of IGF-1. Both GH and IGF-1 activate hormone-sensitive lipase and suppress lipoprotein lipase in adipocytes, promoting lipolysis. Visceral adipose tissue appears to be more sensitive to GH-driven lipolysis than subcutaneous fat, accounting for the preferential VAT reduction seen in trials. Tesamorelin also reduces liver fat independent of changes in VAT volume, possibly via direct hepatic GH receptor signaling [6], and has been shown to improve fat tissue quality (intramyocellular and hepatic lipid content) beyond simple fat-volume metrics [4].
What the evidence says
The pivotal evidence for tesamorelin comes from two independent phase 3 RCTs and a subsequent pooled analysis. Falutz et al. (NEJM, 2007) enrolled 412 HIV-infected patients with abdominal fat accumulation in a 26-week, randomized, double-blind, placebo-controlled trial [1]. Patients receiving tesamorelin 2 mg daily subcutaneously (the original EGRIFTA 1 mg/vial formulation) had visceral adipose tissue on CT decrease by 15.2%, while it increased by 5.0% in the placebo group — a statistically significant and clinically meaningful difference. IGF-1 rose 81.0% in the tesamorelin arm. Patients and their physicians rated abdominal appearance as significantly improved. Glycated hemoglobin (HbA1c) did not differ significantly between arms at 26 weeks.
Falutz et al. (JAIDS, 2010) reported a follow-up RCT with an open-label safety extension through 52 weeks [2]. VAT continued to decrease through 26 weeks, and patients who switched from tesamorelin to placebo during the extension phase regained visceral fat — demonstrating that the drug's effect requires continued use. The pooled phase 3 analysis (Falutz et al., J Clin Endocrinol Metab, 2010) confirmed the primary efficacy results across two independent trials and provided the most robust safety database [3]. A 2026 meta-analysis of all available RCTs (Badran et al.) confirmed significant VAT reduction, hepatic fat improvement, and a favorable metabolic profile with no significant increase in diabetes incidence [5].
Beyond the HIV indication, tesamorelin has shown promise in improving hepatic fat in HIV-infected and non-HIV populations, reducing intrahepatic lipid and FGF-21 levels in a small trial focused on GH augmentation [6]. Lake et al. (AIDS, 2021) demonstrated that tesamorelin improved visceral fat quality (assessed by CT Hounsfield unit density, a marker of adipose tissue inflammation and metabolic dysfunction) independent of the quantity of fat lost [4] — suggesting benefits beyond simple VAT volume reduction. Off-label use in non-HIV populations with excess visceral fat or relative GH deficiency is mechanistically plausible but has not yet been tested in adequately powered RCTs. How that evidence compares with semaglutide and tirzepatide is the subject of tesamorelin vs GLP-1s for fat loss.
A separate line of research explored GHRH agonists for cognitive outcomes. Baker et al. (Arch Neurol, 2012) randomized 152 older adults with or without mild cognitive impairment to GHRH therapy or placebo for 20 weeks; GHRH improved executive function and verbal memory, consistent with IGF-1's role in hippocampal neuroplasticity [7]. The GHRH used was tesamorelin itself, at 1 mg a day by subcutaneous injection. It is a single 20-week trial, and the cognitive benefit has not been confirmed in a larger one.
Typical dosing
The labeled dose depends on the formulation. The phase 3 trials and the original EGRIFTA (1 mg/vial formulation) used 2 mg once daily by subcutaneous injection [1]. The two products with current labels on DailyMed have different doses: EGRIFTA SV (2 mg/vial) is 1.4 mg (0.35 mL of the reconstituted solution) once daily, and EGRIFTA WR is 1.28 mg (0.16 mL) once daily [8] [9]. The SV label states its effectiveness was established from the trials of the 1 mg/vial formulation [8]. The doses differ because the formulations differ, so a dose from one product does not transfer to another. Clinical response was assessed by CT at 26 weeks in the trials [1].
There are no published dose-finding studies in non-HIV populations, so off-label and compounded tesamorelin doses are a prescriber's decision rather than an evidence-based regimen. We do not repeat the reduced-dose or cycling schedules quoted online, which are not taken from published studies. The EGRIFTA SV label tells prescribers to monitor IGF-1 during therapy and to consider stopping in patients with persistent elevations [8].
Safety & side effects
In the phase 3 trials, tesamorelin was generally well tolerated [1][3]. Injection-site reactions (erythema, pruritus, pain) were the most common: the label reports them in 25% of tesamorelin-treated patients versus 14% on placebo over the first 26 weeks [8]. Peripheral edema and arthralgia were reported at low rates. Tesamorelin caused a modest, transient rise in fasting glucose and insulin in some patients, consistent with GH's counter-regulatory effect on insulin; however, HbA1c differences versus placebo were not statistically significant at 26 weeks, and the 2026 meta-analysis found no significant increase in incident diabetes [5]. IGF-1 levels rose substantially (81% in the NEJM trial), which is expected but warrants monitoring in those at risk for IGF-1-sensitive conditions.
Tesamorelin is contraindicated in patients with active malignancy, pituitary tumor or history of pituitary surgery, pregnancy (Category X under old FDA classification), or hypersensitivity to GHRH or any component. Unlike exogenous GH (somatropin), which is associated with acromegaly at supraphysiological doses, tesamorelin's mechanism of amplifying endogenous pulsatile GH preserves the natural feedback axis, theoretically limiting GH overshoot. Long-term safety beyond 52 weeks in HIV populations and beyond any duration in non-HIV populations has not been systematically studied. Compounded tesamorelin sourced outside licensed pharmacies carries additional risks of contamination or mislabeled potency.
Frequently asked questions
What does tesamorelin do?
Tesamorelin makes the pituitary release more of the body's own growth hormone, which raises IGF-1 and breaks down visceral fat. In a 412-patient trial in people with HIV, visceral fat dropped 15.2% in 26 weeks, while it rose 5.0% with placebo [1]. Trials in the same population also found lower liver fat and more lean mass [5]. Its approved use is limited to HIV-associated lipodystrophy.
Tesamorelin side effects: what are the most common?
A 2026 meta-analysis of the randomized trials linked tesamorelin with joint pain, muscle pain, tingling (paresthesia) and injection-site reactions such as redness, without serious side effects or a change in glucose control [5]. In the 412-patient NEJM trial, overall adverse events did not differ from placebo, but more people on tesamorelin dropped out because of one [1]. IGF-1 rose 81% in that trial, which is why the label calls for IGF-1 monitoring [8].
Is tesamorelin the same as CJC-1295?
No. Both are GHRH analogs, but they are structurally distinct compounds with different half-lives, regulatory status, and evidence bases. Tesamorelin (Egrifta) is FDA-approved with phase 3 RCT data. CJC-1295 is not FDA-approved and has only one small human pharmacokinetic study. Tesamorelin has a much stronger evidence base.
How much visceral fat can tesamorelin reduce?
Can people without HIV use tesamorelin?
Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. Off-label use in non-HIV individuals with excess visceral fat, GH deficiency, or NAFLD is practiced but lacks phase 3 trial support in those populations. Mechanistic rationale exists, but individuals without HIV considering tesamorelin should have a thorough workup for GH deficiency and informed discussions about the off-label evidence gap.
Will tesamorelin raise my blood sugar?
GH has counter-regulatory (insulin-opposing) effects that can transiently elevate glucose. In the phase 3 trials, mean HbA1c did not differ significantly between tesamorelin and placebo at 26 weeks, and the 2026 meta-analysis found no significant increase in diabetes incidence [5]. However, people with pre-existing insulin resistance or prediabetes should be closely monitored during treatment.
Is Egrifta (tesamorelin) covered by insurance for HIV lipodystrophy?
Egrifta is FDA-approved for this indication, so coverage is possible through most major insurance plans with appropriate documentation of HIV diagnosis and lipodystrophy. Prior authorization is commonly required. The branded drug is expensive; compounded versions are available but are not bioequivalent by FDA definition and may not satisfy insurance requirements.
How long does it take to see results?
In clinical trials, statistically significant VAT reductions were detectable at 26 weeks with daily subcutaneous dosing [1]. Some patients notice changes in abdominal appearance within 8-12 weeks. Objective CT or DXA measurement at 26 weeks is the standard clinical checkpoint to determine whether to continue therapy.
Sources
- [1] Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med (2007). PMID 18057338
- [2] Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr (2010). PMID 20101189
- [3] Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab (2010). PMID 20554713
- [4] Lake JE, La K, Erlandson KM, et al. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (2021). PMID 33756511
- [5] Badran AS, Helal A, Shata KS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract (2026). PMID 41545261
- [6] Braun LR, Feldpausch MN, Czerwonka N, et al. Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation. Growth Horm IGF Res (2017). PMID 29031905
- [7] Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol (2012). PMID 22869065
- [8] Theratechnologies Inc. EGRIFTA SV (tesamorelin for injection), US Prescribing Information. DailyMed, setid 3d783378-b02d-4f19-99dd-0fc91a042224 (2026). Source
- [9] Theratechnologies Inc. EGRIFTA WR (tesamorelin for injection), US Prescribing Information. DailyMed, setid 839334d3-8c1d-4c26-9036-2ab524a6ea75 (2026). Source
Related peptides
Browse the full peptide directory, see what GLP-1s treat by condition, or compare the best GLP-1 providers.
Educational information only — not medical advice.